Investments today announced that certain closed-end funds have declared their distributions. The table below summarizes the distribution schedule for each closed-end fund (collectively, the “Funds” ...

CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on ...

Cidara will also participate in one-on-one investor meetings during this event. Investors interested in meeting with Cidara ...

A live webcast of the presentation will be available on the investor section of the Anaptys website at https://ir.anaptysbio.com/events. A replay of the webcast will be available for at least 30 days ...

Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that ...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus” or the "Company”), today announced that Yuval Cohen, Ph.D., ...

will present at the Guggenheim SMID Cap Biotech Conference on Wednesday, Feb. 5, 2025 at 1:00pm ET / 10:00am PT. A live webcast of the presentation will be available on the investor section of the ...

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management ...

Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities ...

The live and archived webcast will be accessible from the Company's website at , under the Investors section under Events and Presentations. The replay of the webcast will be accessible for 60 days.

FLORHAM PARK, N.J., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for ...

REDWOOD CITY, Calif. & BOSTON, January 29, 2025--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell ...